ID   AAK1_HUMAN              Reviewed;         961 AA.
AC   Q2M2I8; Q4ZFZ3; Q53RX6; Q9UPV4;
DT   03-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   13-JUL-2010, sequence version 3.
DT   12-OCT-2022, entry version 154.
DE   RecName: Full=AP2-associated protein kinase 1;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:11877457, ECO:0000269|PubMed:11877461, ECO:0000269|PubMed:12952931, ECO:0000269|PubMed:14617351, ECO:0000269|PubMed:17494869, ECO:0000269|PubMed:18657069};
DE   AltName: Full=Adaptor-associated kinase 1;
GN   Name=AAK1; Synonyms=KIAA1048;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   ACTIVITY REGULATION, INTERACTION WITH CLATHRIN AND AP-2, TISSUE
RP   SPECIFICITY, AND DOMAIN.
RC   TISSUE=Brain;
RX   PubMed=17494869; DOI=10.1091/mbc.e06-09-0831;
RA   Henderson D.M., Conner S.D.;
RT   "A novel AAK1 splice variant functions at multiple steps of the endocytic
RT   pathway.";
RL   Mol. Biol. Cell 18:2698-2706(2007).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT GLN-509.
RC   TISSUE=Brain;
RX   PubMed=10470851; DOI=10.1093/dnares/6.3.197;
RA   Kikuno R., Nagase T., Ishikawa K., Hirosawa M., Miyajima N., Tanaka A.,
RA   Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIV. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:197-205(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT GLN-509.
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=11877457; DOI=10.1083/jcb.200111068;
RA   Ricotta D., Conner S.D., Schmid S.L., von Figura K., Honing S.;
RT   "Phosphorylation of the AP2 mu subunit by AAK1 mediates high affinity
RT   binding to membrane protein sorting signals.";
RL   J. Cell Biol. 156:791-795(2002).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=11877461; DOI=10.1083/jcb.200108123;
RA   Conner S.D., Schmid S.L.;
RT   "Identification of an adaptor-associated kinase, AAK1, as a regulator of
RT   clathrin-mediated endocytosis.";
RL   J. Cell Biol. 156:921-929(2002).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH AP-2, AND MUTAGENESIS OF
RP   LYS-74 AND ASP-176.
RX   PubMed=12952931; DOI=10.1083/jcb.200304069;
RA   Conner S.D., Schmid S.L.;
RT   "Differential requirements for AP-2 in clathrin-mediated endocytosis.";
RL   J. Cell Biol. 162:773-779(2003).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND INTERACTION WITH
RP   CLATHRIN AND AP-2.
RX   PubMed=14617351; DOI=10.1046/j.1398-9219.2003.0142.x;
RA   Conner S.D., Schroter T., Schmid S.L.;
RT   "AAK1-mediated micro2 phosphorylation is stimulated by assembled
RT   clathrin.";
RL   Traffic 4:885-890(2003).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-389 AND THR-606, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-389, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-637, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using sequential
RT   IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-389; THR-441; SER-637 AND
RP   SER-731, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-234; SER-235; THR-389;
RP   THR-606; THR-620; SER-623; SER-624 AND SER-637, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH NUMB, AND MUTAGENESIS OF
RP   LYS-74 AND ASP-176.
RX   PubMed=18657069; DOI=10.1111/j.1600-0854.2008.00790.x;
RA   Sorensen E.B., Conner S.D.;
RT   "AAK1 regulates Numb function at an early step in clathrin-mediated
RT   endocytosis.";
RL   Traffic 9:1791-1800(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; THR-354; THR-389;
RP   SER-637; SER-650; TYR-687 AND SER-731, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-389; THR-606; SER-637 AND
RP   THR-653, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-620; SER-623; SER-624 AND
RP   SER-637, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   FUNCTION, INTERACTION WITH EPS15 AND NOTCH1, AND MUTAGENESIS OF LYS-74 AND
RP   777-ASP--PHE-779.
RX   PubMed=21464124; DOI=10.1074/jbc.m110.190769;
RA   Gupta-Rossi N., Ortica S., Meas-Yedid V., Heuss S., Moretti J.,
RA   Olivo-Marin J.C., Israel A.;
RT   "The adaptor-associated kinase 1, AAK1, is a positive regulator of the
RT   Notch pathway.";
RL   J. Biol. Chem. 286:18720-18730(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-606; THR-620; SER-624 AND
RP   SER-637, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [23]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; THR-606; THR-620 AND
RP   SER-637, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-620, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=25653444; DOI=10.1128/jvi.02705-14;
RA   Neveu G., Ziv-Av A., Barouch-Bentov R., Berkerman E., Mulholland J.,
RA   Einav S.;
RT   "AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate
RT   hepatitis C virus entry and are potential drug targets.";
RL   J. Virol. 89:4387-4404(2015).
RN   [27] {ECO:0007744|PDB:4WSQ}
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 29-345 IN COMPLEX WITH INHIBITOR,
RP   AND CATALYTIC ACTIVITY.
RX   PubMed=26853940; DOI=10.1016/j.str.2015.12.015;
RA   Sorrell F.J., Szklarz M., Abdul Azeez K.R., Elkins J.M., Knapp S.;
RT   "Family-wide Structural Analysis of Human Numb-Associated Protein
RT   Kinases.";
RL   Structure 24:401-411(2016).
RN   [28] {ECO:0007744|PDB:5TE0}
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 27-365.
RA   Counago R.M., Elkins J.M., Arrowsmith C.H., Bountra C., Arruda P.,
RA   Edwards A.M., Gileadi O.;
RT   "Crystal Structure of Adaptor Protein 2 Associated Kinase (AAK1) in complex
RT   with BIBF 1120.";
RL   Submitted (SEP-2016) to the PDB data bank.
RN   [29] {ECO:0007744|PDB:5L4Q}
RP   X-RAY CRYSTALLOGRAPHY (1.97 ANGSTROMS) OF 27-365, AND CATALYTIC ACTIVITY.
RX   PubMed=31136173; DOI=10.1021/acs.jmedchem.9b00136;
RA   Verdonck S., Pu S.Y., Sorrell F.J., Elkins J.M., Froeyen M., Gao L.J.,
RA   Prugar L.I., Dorosky D.E., Brannan J.M., Barouch-Bentov R., Knapp S.,
RA   Dye J.M., Herdewijn P., Einav S., De Jonghe S.;
RT   "Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-
RT   pyrrolo[2,3- b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with
RT   Antiviral Activity.";
RL   J. Med. Chem. 62:5810-5831(2019).
RN   [30]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-59; HIS-533; ALA-603; MET-694; THR-725;
RP   ARG-771 AND ASP-835.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Regulates clathrin-mediated endocytosis by phosphorylating
CC       the AP2M1/mu2 subunit of the adaptor protein complex 2 (AP-2) which
CC       ensures high affinity binding of AP-2 to cargo membrane proteins during
CC       the initial stages of endocytosis (PubMed:17494869, PubMed:11877457,
CC       PubMed:11877461, PubMed:12952931, PubMed:14617351, PubMed:25653444).
CC       Isoform 1 and isoform 2 display similar levels of kinase activity
CC       towards AP2M1 (PubMed:17494869). Preferentially, may phosphorylate
CC       substrates on threonine residues (PubMed:11877457, PubMed:18657069).
CC       Regulates phosphorylation of other AP-2 subunits as well as AP-2
CC       localization and AP-2-mediated internalization of ligand complexes
CC       (PubMed:12952931). Phosphorylates NUMB and regulates its cellular
CC       localization, promoting NUMB localization to endosomes
CC       (PubMed:18657069). Binds to and stabilizes the activated form of
CC       NOTCH1, increases its localization in endosomes and regulates its
CC       transcriptional activity (PubMed:21464124).
CC       {ECO:0000269|PubMed:11877457, ECO:0000269|PubMed:11877461,
CC       ECO:0000269|PubMed:12952931, ECO:0000269|PubMed:14617351,
CC       ECO:0000269|PubMed:17494869, ECO:0000269|PubMed:18657069,
CC       ECO:0000269|PubMed:21464124, ECO:0000269|PubMed:25653444}.
CC   -!- FUNCTION: (Microbial infection) By regulating clathrin-mediated
CC       endocytosis, AAK1 plays a role in the entry of hepatitis C virus as
CC       well as for the lifecycle of other viruses such as Ebola and Dengue.
CC       {ECO:0000269|PubMed:25653444, ECO:0000305|PubMed:31136173}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000305};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:11877457,
CC         ECO:0000269|PubMed:11877461, ECO:0000269|PubMed:12952931,
CC         ECO:0000269|PubMed:14617351, ECO:0000269|PubMed:17494869,
CC         ECO:0000269|PubMed:18657069, ECO:0000269|PubMed:26853940,
CC         ECO:0000269|PubMed:31136173};
CC   -!- ACTIVITY REGULATION: Stimulated by clathrin.
CC       {ECO:0000269|PubMed:14617351, ECO:0000269|PubMed:17494869}.
CC   -!- SUBUNIT: Interacts (via CBD domain) with clathrin (PubMed:17494869,
CC       PubMed:14617351). Interacts with AP-2 complex (PubMed:17494869,
CC       PubMed:12952931, PubMed:14617351). Interacts with NUMB
CC       (PubMed:18657069). Interacts with alpha-adaptin (By similarity).
CC       Interacts with EPS15 isoform 2 (PubMed:21464124). Interacts with
CC       membrane-bound activated NOTCH1 but not with the inactive full-length
CC       form of NOTCH1 (PubMed:21464124). Preferentially interacts with
CC       monoubiquitinated activated NOTCH1 compared to the non-ubiquitinated
CC       form (PubMed:21464124). {ECO:0000250|UniProtKB:P0C1X8,
CC       ECO:0000269|PubMed:12952931, ECO:0000269|PubMed:14617351,
CC       ECO:0000269|PubMed:17494869, ECO:0000269|PubMed:18657069,
CC       ECO:0000269|PubMed:21464124}.
CC   -!- INTERACTION:
CC       Q2M2I8; Q9NQ11: ATP13A2; NbExp=2; IntAct=EBI-1383433, EBI-6308763;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:F1MH24};
CC       Peripheral membrane protein {ECO:0000250|UniProtKB:F1MH24}. Membrane,
CC       clathrin-coated pit {ECO:0000269|PubMed:11877461}. Presynapse
CC       {ECO:0000250|UniProtKB:P0C1X8}. Note=Active when found in clathrin-
CC       coated pits at the plasma membrane. In neuronal cells, enriched at
CC       presynaptic terminals. In non-neuronal cells, enriched at leading edge
CC       of migrating cells. {ECO:0000250|UniProtKB:P0C1X8}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=AAK1L {ECO:0000303|PubMed:17494869};
CC         IsoId=Q2M2I8-1; Sequence=Displayed;
CC       Name=2; Synonyms=AAK1S {ECO:0000303|PubMed:17494869};
CC         IsoId=Q2M2I8-2; Sequence=VSP_039459;
CC   -!- TISSUE SPECIFICITY: Detected in brain, heart and liver. Isoform 1 is
CC       the predominant isoform in brain. {ECO:0000269|PubMed:17494869}.
CC   -!- PTM: Autophosphorylated. {ECO:0000269|PubMed:17494869}.
CC   -!- PHARMACEUTICAL: By regulating the entry of hepatitis C virus as well as
CC       the lifecycle of other viruses such as Ebola and Dengue, AAK1 is a
CC       potential drug target for developing antiviral therapies.
CC       {ECO:0000305|PubMed:25653444, ECO:0000305|PubMed:31136173}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA83000.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB028971; BAA83000.2; ALT_INIT; mRNA.
DR   EMBL; AC092431; AAX88861.1; -; Genomic_DNA.
DR   EMBL; AC079121; AAY14931.1; -; Genomic_DNA.
DR   EMBL; AC136007; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC104842; AAI04843.1; -; mRNA.
DR   EMBL; BC111965; AAI11966.1; -; mRNA.
DR   CCDS; CCDS1893.2; -. [Q2M2I8-1]
DR   RefSeq; NP_055726.3; NM_014911.3. [Q2M2I8-1]
DR   PDB; 4WSQ; X-ray; 1.95 A; A/B=29-345.
DR   PDB; 5L4Q; X-ray; 1.97 A; A/B=27-365.
DR   PDB; 5TE0; X-ray; 1.90 A; A=27-365.
DR   PDBsum; 4WSQ; -.
DR   PDBsum; 5L4Q; -.
DR   PDBsum; 5TE0; -.
DR   AlphaFoldDB; Q2M2I8; -.
DR   SMR; Q2M2I8; -.
DR   BioGRID; 116520; 67.
DR   IntAct; Q2M2I8; 47.
DR   MINT; Q2M2I8; -.
DR   STRING; 9606.ENSP00000386456; -.
DR   BindingDB; Q2M2I8; -.
DR   ChEMBL; CHEMBL3830; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q2M2I8; -.
DR   GuidetoPHARMACOLOGY; 1921; -.
DR   GlyGen; Q2M2I8; 7 sites, 2 O-linked glycans (7 sites).
DR   iPTMnet; Q2M2I8; -.
DR   MetOSite; Q2M2I8; -.
DR   PhosphoSitePlus; Q2M2I8; -.
DR   SwissPalm; Q2M2I8; -.
DR   BioMuta; AAK1; -.
DR   DMDM; 300669613; -.
DR   EPD; Q2M2I8; -.
DR   jPOST; Q2M2I8; -.
DR   MassIVE; Q2M2I8; -.
DR   MaxQB; Q2M2I8; -.
DR   PaxDb; Q2M2I8; -.
DR   PeptideAtlas; Q2M2I8; -.
DR   PRIDE; Q2M2I8; -.
DR   ProteomicsDB; 61355; -. [Q2M2I8-1]
DR   ProteomicsDB; 61356; -. [Q2M2I8-2]
DR   Antibodypedia; 7943; 368 antibodies from 38 providers.
DR   DNASU; 22848; -.
DR   Ensembl; ENST00000406297.7; ENSP00000385181.3; ENSG00000115977.21. [Q2M2I8-2]
DR   Ensembl; ENST00000409085.9; ENSP00000386456.3; ENSG00000115977.21. [Q2M2I8-1]
DR   GeneID; 22848; -.
DR   KEGG; hsa:22848; -.
DR   MANE-Select; ENST00000409085.9; ENSP00000386456.3; NM_014911.5; NP_055726.4.
DR   UCSC; uc002sfp.3; human. [Q2M2I8-1]
DR   CTD; 22848; -.
DR   DisGeNET; 22848; -.
DR   GeneCards; AAK1; -.
DR   HGNC; HGNC:19679; AAK1.
DR   HPA; ENSG00000115977; Tissue enhanced (parathyroid).
DR   MIM; 616405; gene.
DR   neXtProt; NX_Q2M2I8; -.
DR   OpenTargets; ENSG00000115977; -.
DR   PharmGKB; PA134990616; -.
DR   VEuPathDB; HostDB:ENSG00000115977; -.
DR   eggNOG; KOG1989; Eukaryota.
DR   GeneTree; ENSGT00940000155968; -.
DR   InParanoid; Q2M2I8; -.
DR   OMA; ASLNKSX; -.
DR   OrthoDB; 826336at2759; -.
DR   PhylomeDB; Q2M2I8; -.
DR   TreeFam; TF317300; -.
DR   PathwayCommons; Q2M2I8; -.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   SignaLink; Q2M2I8; -.
DR   SIGNOR; Q2M2I8; -.
DR   BioGRID-ORCS; 22848; 19 hits in 1111 CRISPR screens.
DR   ChiTaRS; AAK1; human.
DR   GeneWiki; AAK1; -.
DR   GenomeRNAi; 22848; -.
DR   Pharos; Q2M2I8; Tchem.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q2M2I8; protein.
DR   Bgee; ENSG00000115977; Expressed in lateral nuclear group of thalamus and 213 other tissues.
DR   ExpressionAtlas; Q2M2I8; baseline and differential.
DR   Genevisible; Q2M2I8; HS.
DR   GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-KW.
DR   GO; GO:0031252; C:cell leading edge; ISS:UniProtKB.
DR   GO; GO:0005905; C:clathrin-coated pit; IEA:UniProtKB-SubCell.
DR   GO; GO:0030136; C:clathrin-coated vesicle; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0019897; C:extrinsic component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0043195; C:terminal bouton; ISS:UniProtKB.
DR   GO; GO:0035612; F:AP-2 adaptor complex binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005112; F:Notch binding; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IDA:UniProtKB.
DR   GO; GO:2000369; P:regulation of clathrin-dependent endocytosis; IDA:UniProtKB.
DR   GO; GO:0032880; P:regulation of protein localization; IDA:UniProtKB.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cell membrane; Cell projection; Coated pit; Endocytosis; Kinase; Membrane;
KW   Methylation; Nucleotide-binding; Pharmaceutical; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Synapse; Transferase.
FT   CHAIN           1..961
FT                   /note="AP2-associated protein kinase 1"
FT                   /id="PRO_0000250578"
FT   DOMAIN          46..315
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..25
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          327..493
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          562..632
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          664..701
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          823..960
FT                   /note="Clathrin-binding domain (CBD)"
FT                   /evidence="ECO:0000269|PubMed:17494869"
FT   REGION          836..860
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          921..945
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        353..382
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        399..414
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        416..443
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        444..493
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        562..577
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        598..627
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        843..860
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        929..945
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        176
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         52..60
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         74
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
FT   MOD_RES         14
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         234
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         235
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         354
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         389
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         391
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UHJ0"
FT   MOD_RES         441
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         606
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         618
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P0C1X8"
FT   MOD_RES         620
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         623
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         624
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT   MOD_RES         637
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19367720,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         650
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         653
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         687
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         731
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         846
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UHJ0"
FT   MOD_RES         937
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UHJ0"
FT   MOD_RES         938
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UHJ0"
FT   VAR_SEQ         823..961
FT                   /note="EKADVAVESLIPGLEPPVPQRLPSQTESVTSNRTDSLTGEDSLLDCSLLSNP
FT                   TTDLLEEFAPTAISAPVHKAAEDSNLISGFDVPEGSDKVAEDEFDPIPVLITKNPQGGH
FT                   SRNSSGSSESSLPNLARSLLLVDQLIDL -> GKVIISVSSVMHDMCACFKNDKYLVNQ
FT                   SLGNSPATPEAKAI (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10470851,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_039459"
FT   VARIANT         59
FT                   /note="I -> V (in dbSNP:rs34535244)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040348"
FT   VARIANT         509
FT                   /note="K -> Q (in dbSNP:rs6715776)"
FT                   /evidence="ECO:0000269|PubMed:10470851,
FT                   ECO:0000269|PubMed:15489334"
FT                   /id="VAR_031129"
FT   VARIANT         533
FT                   /note="Q -> H (in dbSNP:rs1263928487)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040349"
FT   VARIANT         603
FT                   /note="V -> A (in dbSNP:rs56038532)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040350"
FT   VARIANT         694
FT                   /note="T -> M (in dbSNP:rs55889248)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040351"
FT   VARIANT         725
FT                   /note="P -> T (in dbSNP:rs35285785)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040352"
FT   VARIANT         771
FT                   /note="P -> R (in dbSNP:rs34422616)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040353"
FT   VARIANT         835
FT                   /note="G -> D"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040354"
FT   MUTAGEN         74
FT                   /note="K->A: Inhibits autophosphorylation and
FT                   phosphorylation of AP2M1. Does not affect NUMB
FT                   localization. Does not interact with monoubiquitinated
FT                   NOTCH1."
FT                   /evidence="ECO:0000269|PubMed:12952931,
FT                   ECO:0000269|PubMed:18657069, ECO:0000269|PubMed:21464124"
FT   MUTAGEN         176
FT                   /note="D->A: Inhibits autophosphorylation and
FT                   phosphorylation of AP2M1. Does not affect NUMB
FT                   localization."
FT                   /evidence="ECO:0000269|PubMed:12952931,
FT                   ECO:0000269|PubMed:18657069"
FT   MUTAGEN         777..779
FT                   /note="DPF->AAA: Does not affect interaction with NOTCH1
FT                   but abolishes interaction with ESP15."
FT                   /evidence="ECO:0000269|PubMed:21464124"
FT   HELIX           31..34
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   STRAND          38..41
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   STRAND          44..55
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   STRAND          58..64
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   STRAND          70..78
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   HELIX           81..97
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   STRAND          106..113
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   STRAND          120..127
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   HELIX           134..139
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   TURN            142..144
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   HELIX           148..167
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   STRAND          168..170
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   HELIX           179..181
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   STRAND          182..184
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   STRAND          190..192
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   HELIX           205..208
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   HELIX           210..220
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   HELIX           223..225
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   HELIX           228..231
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   HELIX           242..257
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   TURN            261..264
FT                   /evidence="ECO:0007829|PDB:4WSQ"
FT   HELIX           266..271
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   HELIX           284..293
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   TURN            298..300
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   HELIX           304..315
FT                   /evidence="ECO:0007829|PDB:5TE0"
FT   HELIX           339..344
FT                   /evidence="ECO:0007829|PDB:5TE0"
SQ   SEQUENCE   961 AA;  103885 MW;  1FB44D0FDEF6CAD0 CRC64;
     MKKFFDSRRE QGGSGLGSGS SGGGGSTSGL GSGYIGRVFG IGRQQVTVDE VLAEGGFAIV
     FLVRTSNGMK CALKRMFVNN EHDLQVCKRE IQIMRDLSGH KNIVGYIDSS INNVSSGDVW
     EVLILMDFCR GGQVVNLMNQ RLQTGFTENE VLQIFCDTCE AVARLHQCKT PIIHRDLKVE
     NILLHDRGHY VLCDFGSATN KFQNPQTEGV NAVEDEIKKY TTLSYRAPEM VNLYSGKIIT
     TKADIWALGC LLYKLCYFTL PFGESQVAIC DGNFTIPDNS RYSQDMHCLI RYMLEPDPDK
     RPDIYQVSYF SFKLLKKECP IPNVQNSPIP AKLPEPVKAS EAAAKKTQPK ARLTDPIPTT
     ETSIAPRQRP KAGQTQPNPG ILPIQPALTP RKRATVQPPP QAAGSSNQPG LLASVPQPKP
     QAPPSQPLPQ TQAKQPQAPP TPQQTPSTQA QGLPAQAQAT PQHQQQLFLK QQQQQQQPPP
     AQQQPAGTFY QQQQAQTQQF QAVHPATQKP AIAQFPVVSQ GGSQQQLMQN FYQQQQQQQQ
     QQQQQQLATA LHQQQLMTQQ AALQQKPTMA AGQQPQPQPA AAPQPAPAQE PAIQAPVRQQ
     PKVQTTPPPA VQGQKVGSLT PPSSPKTQRA GHRRILSDVT HSAVFGVPAS KSTQLLQAAA
     AEASLNKSKS ATTTPSGSPR TSQQNVYNPS EGSTWNPFDD DNFSKLTAEE LLNKDFAKLG
     EGKHPEKLGG SAESLIPGFQ STQGDAFATT SFSAGTAEKR KGGQTVDSGL PLLSVSDPFI
     PLQVPDAPEK LIEGLKSPDT SLLLPDLLPM TDPFGSTSDA VIEKADVAVE SLIPGLEPPV
     PQRLPSQTES VTSNRTDSLT GEDSLLDCSL LSNPTTDLLE EFAPTAISAP VHKAAEDSNL
     ISGFDVPEGS DKVAEDEFDP IPVLITKNPQ GGHSRNSSGS SESSLPNLAR SLLLVDQLID
     L
//
